For research use only
| Cat No. | ABC-TC0180 |
| Product Type | Human Lung Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lymph Node |
| Disease | Lung Small Cell Cancer |
| Product Code | COR L24; Cor L24; CORL24 |
COR-L24 cell line is a human lung cancer model widely used for oncology research, molecular pathway studies, and drug discovery applications in vitro.
COR L24 is a human small cell lung carcinoma (SCLC) cell line established in 1985 from a lymph node biopsy of an untreated 71-year-old male patient. These cells grow as floating aggregates of densely packed, irregularly shaped epithelial-like cells and can be continuously passaged in suspension culture. COR L24 cells exhibit classic neuroendocrine features, expressing typical SCLC markers such as neuropeptides, making them widely used in immunocytochemistry studies. Transcriptomic analysis reveals distinct molecular characteristics, with altered expression of over 2,000 genes compared to other cell lines. Genomic profiling identifies key mutations, including a homozygous truncating mutation in the tumor suppressor gene APC (p.Glu1554Ter) and a heterozygous missense mutation in TP53 (p.Tyr234Cys). These cells are tumorigenic in vivo and serve as a valuable model for investigating SCLC biology, therapeutic responses, and signaling pathways.
| Product Code | COR L24; Cor L24; CORL24 |
| Species | Human |
| Cat.No | ABC-TC0180 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lymph Node |
| Disease | Lung Small Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
The COR-L24 cell line advances small cell lung carcinoma (SCLC) research by modeling pathobiology, molecular characteristics, and therapeutic responses. It facilitates therapeutic drug screening to evaluate anti-cancer agents for novel drug development while supporting immunocytochemistry studies analyzing SCLC-specific markers and neuroendocrine differentiation for cellular characterization.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
